Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.

Zhao H, Ning Y, Cooper J, Refoios Camejo R, Ni X, Yi B, Parks D.

Adv Ther. 2019 Jun;36(6):1252-1265. doi: 10.1007/s12325-019-00938-1. Epub 2019 Apr 8. Review.

PMID:
30963514
2.

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Kulisevsky J, Pagonabarraga J.

Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860-000000000-00000. Review.

PMID:
20082541
3.

Ropinirole: a review of its use in the management of Parkinson's disease.

Matheson AJ, Spencer CM.

Drugs. 2000 Jul;60(1):115-37. Review.

PMID:
10929932
4.

Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.

Thorlund K, Wu P, Druyts E, Eapen S, Mills EJ.

Neuropsychiatr Dis Treat. 2014 May 7;10:767-76. doi: 10.2147/NDT.S60061. eCollection 2014.

5.

Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.

Li BD, Cui JJ, Song J, Qi C, Ma PF, Wang YR, Bai J.

Cell Physiol Biochem. 2018;45(1):119-130. doi: 10.1159/000486252. Epub 2018 Jan 15.

6.

Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.

Inzelberg R, Schechtman E, Nisipeanu P.

Drugs Aging. 2003;20(11):847-55. Review.

PMID:
12964891
7.
8.

Pramipexole for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002261. Review.

PMID:
10908540
9.

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Dooley M, Markham A.

Drugs Aging. 1998 Jun;12(6):495-514. Review.

PMID:
9638397
10.

Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.

Shen T, Ye R, Zhang B.

Eur J Neurol. 2017 Jun;24(6):835-843. doi: 10.1111/ene.13303. Epub 2017 May 8. Review.

PMID:
28480621
11.

The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.

Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, Liu C, Qu Q, Cheng Y, Li J, Cao H, Cai M, Zhu R.

Parkinsonism Relat Disord. 2013 Nov;19(11):1022-6. doi: 10.1016/j.parkreldis.2013.07.009. Epub 2013 Aug 6. Erratum in: Parkinsonism Relat Disord. 2014 Aug;20(8):943-4.

PMID:
23932066
12.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
14.

Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.

Zhou CQ, Zhang JW, Wang M, Peng GG.

J Clin Neurosci. 2014 Jul;21(7):1094-101. doi: 10.1016/j.jocn.2013.10.041. Epub 2014 Apr 29. Review.

PMID:
24786715
15.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.

Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317.

PMID:
20669317
16.

Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002259. Review.

PMID:
10908539
17.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001516. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001516.

PMID:
10908503
18.

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.

Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, Finnern HW.

Sleep Med. 2008 Oct;9(7):715-26. doi: 10.1016/j.sleep.2007.11.020. Epub 2008 Jan 28.

PMID:
18226947
19.

Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W.

Eur J Neurol. 2013 Jan;20(1):180-7. doi: 10.1111/j.1468-1331.2012.03822.x. Epub 2012 Jul 31.

PMID:
22845710
20.

Rotigotine transdermal system for the treatment of Parkinson's disease.

Pham DQ, Nogid A.

Clin Ther. 2008 May;30(5):813-24. doi: 10.1016/j.clinthera.2008.05.007. Review.

PMID:
18555929

Supplemental Content

Support Center